This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mejías, A.
Right arrow Articles by Ramilo, O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mejías, A.
Right arrow Articles by Ramilo, O.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2004, p. 1811-1822, Vol. 48, No. 5
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.5.1811-1822.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Anti-Respiratory Syncytial Virus (RSV) Neutralizing Antibody Decreases Lung Inflammation, Airway Obstruction, and Airway Hyperresponsiveness in a Murine RSV Model

Asunción Mejías,1 Susana Chávez-Bueno,1 Ana María Ríos,1 Jesús Saavedra-Lozano,1 Mónica Fonseca Aten,1 Jeanine Hatfield,1 Payal Kapur,2 Ana María Gómez,2 Hasan S. Jafri,1 and Octavio Ramilo1*

Department of Pediatrics, Division of Pediatric Infectious Diseases,1 Department of Pathology, University of Texas Southwestern Medical Center at Dallas and Children's Medical Center of Dallas, Dallas, Texas2

Received 7 June 2003/ Returned for modification 17 August 2003/ Accepted 19 January 2004

Numerous studies have described a strong association between respiratory syncytial virus (RSV) infection in infancy and the development of recurrent wheezing and airway hyperresponsiveness. We evaluated the effect of an anti-RSV neutralizing monoclonal antibody (palivizumab) on different aspects of RSV disease by using a murine model. BALB/c mice were intranasally inoculated with RSV A2. Palivizumab or an isotype-matched control antibody was administered once at 24 h before inoculation, 1 h after inoculation, or 48 h after inoculation. Regardless of the timing of administration, all mice treated with the neutralizing antibody showed significantly decreased RSV loads in bronchoalveolar lavage (BAL) and lung specimens compared with those of infected controls. Pulmonary histopathologic scores, airway obstruction measured by plethysmography, and airway hyperresponsiveness after methacholine challenge were significantly reduced in mice treated with the anti-RSV antibody 24 h before inoculation compared with those for untreated controls. Concentrations of interferon-gamma, interleukin-10, macrophage inflammatory protein 1{alpha}, regulated on activation normal T-cell expressed and secreted (RANTES), and eotaxin in BAL fluids were also significantly reduced in mice treated with palivizumab 24 h before inoculation. This study demonstrates that reduced RSV replication was associated with significant modulation of inflammatory and clinical markers of acute disease severity and significant improvement of the long-term pulmonary abnormalities. Studies to determine whether strategies aimed at preventing or reducing RSV replication could decrease the long-term morbidity associated with RSV infection in children should be considered.

* Corresponding author. Mailing address: Department of Pediatrics, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390-9063. Phone: (214) 648-1261. Fax: (214) 648-1265. E-mail: octavio.ramilo{at}utsouthwestern.edu.

Antimicrobial Agents and Chemotherapy, May 2004, p. 1811-1822, Vol. 48, No. 5
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.5.1811-1822.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Miao, C., Radu, G. U., Caidi, H., Tripp, R. A., Anderson, L. J., Haynes, L. M. (2009). Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(ab')2 components mediates reduced pulmonary inflammation in mice. J. Gen. Virol. 90: 1119-1123 [Abstract] [Full Text]  
  • Mejias, A., Chavez-Bueno, S., Rios, A. M., Aten, M. F., Raynor, B., Peromingo, E., Soni, P., Olsen, K. D., Kiener, P. A., Gomez, A. M., Jafri, H. S., Ramilo, O. (2005). Comparative Effects of Two Neutralizing Anti-Respiratory Syncytial Virus (RSV) Monoclonal Antibodies in the RSV Murine Model: Time versus Potency. Antimicrob. Agents Chemother. 49: 4700-4707 [Abstract] [Full Text]  
  • Hamelin, M.-E., Yim, K., Kuhn, K. H., Cragin, R. P., Boukhvalova, M., Blanco, J. C. G., Prince, G. A., Boivin, G. (2005). Pathogenesis of Human Metapneumovirus Lung Infection in BALB/c Mice and Cotton Rats. J. Virol. 79: 8894-8903 [Abstract] [Full Text]  
  • Openshaw, P. J. M., Tregoning, J. S. (2005). Immune Responses and Disease Enhancement during Respiratory Syncytial Virus Infection. Clin. Microbiol. Rev. 18: 541-555 [Abstract] [Full Text]  
  • Mejias, A., Chavez-Bueno, S., Sanchez, P. J. (2005). Respiratory Syncytial Virus Prophylaxis. NeoReviews 6: e26-e31 [Full Text]  
  • Empey, K. M., Hollifield, M., Schuer, K., Gigliotti, F., Garvy, B. A. (2004). Passive Immunization of Neonatal Mice against Pneumocystis carinii f. sp. muris Enhances Control of Infection without Stimulating Inflammation. Infect. Immun. 72: 6211-6220 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»